871357-92-5Relevant articles and documents
Development and scale-up of an optimized route to the ALK inhibitor CEP-28122
Allwein, Shawn P.,Roemmele, Renee C.,Haley, James J.,Mowrey, Dale R.,Petrillo, Daniel E.,Reif, James J.,Gingrich, Diane E.,Bakale, Roger P.
, p. 148 - 155 (2012)
Evolution of the process strategies to prepare CEP-28122, an anaplastic lymphoma kinase (ALK) inhibitor, is presented. The initial medicinal chemistry route, used for the preparation of key supplies for biological screening, is reviewed. In addition, the